The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Open accessAbstract
Enhancers, critical determinants of cellular identity, are commonly recognized by correlative chromatin marks and gain-of-function potential, although only loss-of-function studies can demonstrate their requirement in the native genomic context. Previously, we identified an erythroid enhancer of human BCL11A, subject to common genetic variation associated with the fetal haemoglobin level, the mouse orthologue of which is necessary for erythroid BCL11A expression. Here we develop pooled clustered regularly interspaced palindromic repeat (CRISPR)-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and mouse enhancers. This approach reveals critical minimal features and discrete vulnerabilities of these enhancers. Despite conserved function of the composite enhancers, their architecture diverges. The crucial human sequences appear to be primate-specific. Through editing of primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a target for fetal haemoglobin reinduction. The detailed enhancer map will inform therapeutic genome editing, and the screening approach described here is generally applicable to functional interrogation of non-coding genomic elements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The authors flow-sorted the edited cells on the basis of the BCL11A-dependent switch to fetal haemoglobin, sequenced guides enriched in cells that had or hadn’t switched, and on the basis of those enrichments, successfully identified a primate-specific GATA1 motif critical for that enhancer’s function.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Cas9 introduces a targeted double-strand break, which is repaired by homology-directed repair using the donor templates, resulting in the incorporation of a single variant at the endogenous genomic locus (54, 55).”
From Massively parallel functional genomic assays in endocrinology: from promise to delivery (2026) · cites this paper as [54]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first such screen targeted gRNAs to effectively tile small indels across a known cluster of enhancers of BCL11A195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Canver et al 9 recently showed BCL11A enhancer disruption by CRISPR/Cas9 could induce fetal haemoglobin in both mice and primary human erythroblast cells.”
From What is CRISPR/Cas9? (2016) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The initial CRISPR screens of regulatory elements delivered an individual gRNA per cell195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
The cited source says what the claim attributes to it.
In the citing paper
“To date, all such screens use Cas9-induced perturbations, including active Cas9 for sequence disruption195, or nuclease dead-Cas9 (dCas9) tethered to an epigenetic repressor105 or activator domain92.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
In the citing paper
“In contrast, nine recently published CRISPR screens of noncoding sequences cumulatively studied regulatory effects on a total of 17 genes (Canver et al., 2015; Diao et al., 2016, 2017; Fulco et al., 2016; Gasperini et al., 2017; Klann et al., 2017; Korkmaz et al., 2016; Rajagopal et al., 2016; Sanjana et al., 2016).”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
In the citing paper
“First, they focus on the regulation of a single gene per experiment, typically entailing the development of a gene-specific assay.”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationRNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Self-citationGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHistone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
FIMO: scanning for occurrences of a given motif
Grant, C. E., Bailey, T. L., & Noble, W. S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr064 · Cited by 4,247
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Systematic Localization of Common Disease-Associated Variation in Regulatory DNA
Maurano, M. T., Humbert, R., Rynes, E., Thurman, R. E., Haugen, E., Wang, H., Reynolds, A. P., Sandstrom, R., Qu, H., Brody, J., et al. (2012) · Science · doi:10.1126/science.1222794 · Cited by 3,716
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
Self-citation
Flagged first, then by citations
2 of the 65 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 883
Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion
Freeman, A. J., Vervoort, S. J., Ramsbottom, K. M., Kelly, M. J., Michie, J., Pijpers, L., Johnstone, R. W., Kearney, C. J., & Oliaro, J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.017 · Cited by 140
Gene Regulatory Elements, Major Drivers of Human Disease
Chatterjee, S., & Ahituv, N. (2017) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091416-035537 · Cited by 144
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
Prakash, V., Moore, M., & Yáñez‐Muñoz, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.5 · Cited by 138
Yamauchi, T., Masuda, T., Canver, M. C., Seiler, M., Semba, Y., Shboul, M., Al‐Raqad, M., Maeda, M., Schoonenberg, V. A. C., Cole, M. A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.012 · Cited by 139
Self-citationLiu, C., Dong, W. G., Xiang, J., Ren, F., Huang, L., Lang, J., Tian, G., Li, Y., & Yang, J. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.003 · Cited by 138
Lattanzi, A., Meneghini, V., Pavani, G., Amor, F., Ramadier, S., Félix, T., Antoniani, C., Masson, C., Alibeu, O., Lee, C. M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.008 · Cited by 144
RNA‐based medicine: from molecular mechanisms to therapy
Sparmann, A., & Vogel, J. (2023) · The EMBO Journal · doi:10.15252/embj.2023114760 · Cited by 151
RNAi/CRISPR Screens: from a Pool to a Valid Hit
Schuster, A. M., Erasimus, H., Fritah, S., Nazarov, P. V., Dyck, E. V., Niclou, S. P., & Golebiewska, A. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.08.002 · Cited by 140
A new class of temporarily phenotypic enhancers identified by CRISPR/Cas9-mediated genetic screening
Diao, Y., Li, B., Meng, Z., Jung, I., Lee, A. Y., Dixon, J., Maliskova, L., Guan, K.-L., Shen, Y., & Ren, B. (2016) · Genome Research · doi:10.1101/gr.197152.115 · Cited by 122
Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases
Wu, S., Li, Q.-C., Yin, C., Xue, W., & Song, C. (2020) · Theranostics · doi:10.7150/thno.43360 · Cited by 145
Chong, R., Insigne, K. D., Yao, D., Burghard, C. P., Wang, J., Hsiao, Y.-H. E., Jones, E. M., Goodman, D. B., Xiao, X., & Kosuri, S. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.10.037 · Cited by 130
Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review)
Rodríguez-Rodríguez, D. R., Ram�rez‐Sol�s, R., Garza‐Elizondo, M. A., Garza‐Rodr�guez, M., & Barrera-Saldaña, H. A. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4112 · Cited by 145
Non-coding driver mutations in human cancer
Elliott, K., & Larsson, E. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00371-z · Cited by 137
Minireview: Genetic basis of heterogeneity and severity in sickle cell disease
Habara, A. H., & Steinberg, M. H. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216636726 · Cited by 133
The NIH Somatic Cell Genome Editing program
Saha, K., Sontheimer, E. J., Brooks, P. J., Dwinell, M. R., Gersbach, C. A., Liu, D. R., Murray, S. A., Tsai, S. Q., Wilson, R. C., Anderson, D. G., et al. (2021) · Nature · doi:10.1038/s41586-021-03191-1 · Cited by 127
Gene Therapy for β-Hemoglobinopathies
Cavazzana, M., Antoniani, C., & Miccio, A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.024 · Cited by 132
Characterization of noncoding regulatory DNA in the human genome
Elkon, R., & Agami, R. (2017) · Nature Biotechnology · doi:10.1038/nbt.3863 · Cited by 132
Human genetic diversity alters off-target outcomes of therapeutic gene editing
Cancellieri, S., Zeng, J., Lin, L. Y., Tognon, M., Nguyen, M. A., Lin, J., Bombieri, N., Maitland, S. A., Ciuculescu, M.-F., Katta, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01257-y · Cited by 125
Self-citationEpigenome editing technologies for discovery and medicine
McCutcheon, S. R., Rohm, D., Iglesias, N., & Gersbach, C. A. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02320-1 · Cited by 130
Emerging genetic therapy for sickle cell disease
Orkin, S. H., & Bauer, D. E. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041817-125507 · Cited by 119
Self-citationEngineering Delivery Vehicles for Genome Editing
Nelson, C. E., & Gersbach, C. A. (2016) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-080615-034711 · Cited by 120
Gene therapy for sickle cell disease: An update
Demirci, S., Uchida, N., & Tisdale, J. F. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.04.003 · Cited by 126
Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies
Vinjamur, D. S., Bauer, D. E., & Orkin, S. H. (2018) · British Journal of Haematology · doi:10.1111/bjh.15038 · Cited by 114
Self-citationWake-up Sleepy Gene: Reactivating Fetal Globin for β-Hemoglobinopathies
Wienert, B., Martyn, G. E., Funnell, A. P. W., Quinlan, K. G. R., & Crossley, M. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.09.004 · Cited by 115
Psatha, N., Reik, A., Phelps, S. R., Zhou, Y., Dalas, D., Yannaki, E., Levasseur, D. N., Urnov, F. D., Holmes, M. C., & Papayannopoulou, T. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.08.003 · Cited by 120
Lessard, S., Francioli, L. C., Alföldi, J., Tardif, J., Ellinor, P. T., MacArthur, D. G., Lettre, G., Orkin, S. H., & Canver, M. C. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714640114 · Cited by 115
Self-citationCRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments
Laurent, M., Geoffroy, M., Pavani, G., & Guiraud, S. (2024) · Cells · doi:10.3390/cells13100800 · Cited by 126
Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis
Sher, F., Hossain, M. A., Seruggia, D., Schoonenberg, V. A. C., Yao, Q., Cifani, P., Dassama, L. M. K., Cole, M. A., Ren, C., Vinjamur, D. S., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0453-4 · Cited by 113
Self-citationHumbert, O., Radtke, S., Samuelson, C., Carrillo, R. R., Perez, A. M., Reddy, S. S., Lux, C. T., Pattabhi, S., Schefter, L. E., Nègre, O., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw3768 · Cited by 112
Cai, L., Bai, H., Mahairaki, V., Gao, Y., He, C., Wen, Y., Jin, Y.-C., Wang, Y., Pan, R. L., Qasba, A., et al. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0066 · Cited by 111
Enhanced Cas12a editing in mammalian cells and zebrafish
Liu, P., Luk, K., Shin, M., Idrizi, F., Kwok, S. F., Roscoe, B. P., Mintzer, E., Suresh, S., Morrison, K. S., Frazão, J. B., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz184 · Cited by 103
Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies
Lettre, G., & Bauer, D. E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01341-0 · Cited by 104
Self-citationThe Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases
Abdelnour, S. A., Xie, L., Hassanin, A. A., Zuo, E., & Lu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.699597 · Cited by 121
CRISPR-based therapeutics: current challenges and future applications
Modell, A. E., Lim, D., Nguyen, T. M., Sreekanth, V., & Choudhary, A. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.10.012 · Cited by 114
Canver, M. C., Lessard, S., Pinello, L., Wu, Y., Ilboudo, Y., Stern, E. N., Needleman, A. J., Galactéros, F., Brugnara, C., Kutlar, A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3793 · Cited by 105
Self-citationCRISPR/Cas9 gene editing for curing sickle cell disease
Park, S. H., & Bao, G. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103060 · Cited by 118
Mettananda, S., Fisher, C. A., Hay, D., Badat, M., Quek, L. S., Clark, K., Hublitz, P., Downes, D. J., Kerry, J., Gosden, M. E., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00479-7 · Cited by 104
Molecular and cellular mechanisms that regulate human erythropoiesis
Caulier, A., & Sankaran, V. G. (2021) · Blood · doi:10.1182/blood.2021011044 · Cited by 118
Neurobiological functions of transcriptional enhancers
Nord, A. S., & West, A. E. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0538-5 · Cited by 106
Transcription imparts architecture, function and logic to enhancer units
Tippens, N. D., Liang, J. H., Leung, A. K.-Y., Wierbowski, S. D., Ozer, A., Booth, J. G., Lis, J. T., & Yu, H. (2020) · Nature Genetics · doi:10.1038/s41588-020-0686-2 · Cited by 104
Advances in the Treatment of Sickle Cell Disease
Kapoor, S., Little, J. A., & Pecker, L. H. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.001 · Cited by 110
CRISPR screens in plants: approaches, guidelines, and future prospects
Gaillochet, C., Develtere, W., & Jacobs, T. B. (2021) · The Plant Cell · doi:10.1093/plcell/koab099 · Cited by 102
Singh, A., Irfan, H., Fatima, E., Nazir, Z., Verma, A., & Akilimali, A. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002146 · Cited by 127
Identification of non-coding silencer elements and their regulation of gene expression
Pang, B., van Weerd, J. H., Hamoen, F. L., & Snyder, M. P. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00549-9 · Cited by 103
Functional Genomics via CRISPR–Cas
Ford, K. M., McDonald, D., & Mali, P. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.034 · Cited by 103
Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies
Magrin, E., Miccio, A., & Cavazzana, M. (2019) · Blood · doi:10.1182/blood.2019000949 · Cited by 100
A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction
Ting, P. Y., Borikar, S., Kerrigan, J. R., Thomsen, N. M., Aghania, E., Hinman, A. E., Reyes, A., Pizzato, N., Fodor, B. D., Wu, F., et al. (2024) · Science · doi:10.1126/science.adk6129 · Cited by 97
Ahmadi, S. E., Soleymani, M., Shahriyary, F., Amirzargar, M. R., Mahya, O., Fattahi, D., & Safa, M. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00597-z · Cited by 97
KLF1 drives the expression of fetal hemoglobin in British HPFH
Wienert, B., Martyn, G. E., Kurita, R., Nakamura, Y., Quinlan, K. G. R., & Crossley, M. (2017) · Blood · doi:10.1182/blood-2017-02-767400 · Cited by 94
Self-citationGenome‐wide association studies in Crohn's disease: Past, present and future
Verstockt, B., Smith, K. G. C., & Lee, J. C. (2018) · Clinical & Translational Immunology · doi:10.1002/cti2.1001 · Cited by 97
Li, C., Georgakopoulou, A., Mishra, A., Gil, S., Hawkins, R. D., Yannaki, E., & Lieber, A. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003702 · Cited by 96
CRISPR library designer (CLD): software for multispecies design of single guide RNA libraries
Heigwer, F., Zhan, T., Breinig, M., Winter, J., Brügemann, D., Leible, S., & Boutros, M. (2016) · Genome biology · doi:10.1186/s13059-016-0915-2 · Cited by 92
Deciphering the impact of genomic variation on function
Writing group (ordered by contribution), Engreitz, J., Lawson, H. A., Singh, H., Starita, L. M., Hon, G. C., Carter, H. K., Sahni, N., Reddy, T. E., Lin, X., et al. (2024) · Nature · doi:10.1038/s41586-024-07510-0 · Cited by 105
Self-citationXue, M., Dong, L., Zhang, H., Li, Y., Qiu, K., Zhao, Z., Gao, M., Han, L., Chan, A., Li, W., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01526-9 · Cited by 93
Scalable Design of Paired CRISPR Guide RNAs for Genomic Deletion
Pulido-Quetglas, C., Aparicio-Prat, E., Arnan, C., Polidori, T., Hermoso, A., Palumbo, E., Ponomarenko, J. V., Guigó, R., & Johnson, R. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005341 · Cited by 90
Transcription factor competition at the γ-globin promoters controls hemoglobin switching
Liu, N., Xu, S., Yao, Q., Zhu, Q., Yan, K., Hsu, J. Y., Sakon, P., Pinello, L., Yuan, G., Bauer, D. E., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00798-y · Cited by 86
Self-citationReilly, S. K., Gosai, S. J., Gutierrez, A., Mackay-Smith, A., Ulirsch, J. C., Kanai, M., Mouri, K., Berenzy, D., Kales, S., Butler, G. M., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00900-4 · Cited by 86
Shin, J. J., Schröder, M., Caiado, F., Wyman, S. K., Bray, N., Bordi, M., DeWitt, M. A., Vu, J. T., Kim, W., Hockemeyer, D. F., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108093 · Cited by 87
Therapeutic adenine base editing of human hematopoietic stem cells
Liao, J., Chen, S., Hsiao, S., Jiang, Y., Yang, Y., Zhang, Y., Wang, X., Lai, Y., Bauer, D. E., & Wu, Y. (2023) · Nature Communications · doi:10.1038/s41467-022-35508-7 · Cited by 89
Self-citationModeling cis-regulation with a compendium of genome-wide histone H3K27ac profilesPreprint
Wang, S., Zang, C., Xiao, T., Fan, J., Mei, S., Qin, Q., Wu, Q., Li, X., Xu, K., He, H. H., et al. (2016) · Genome Research · doi:10.1101/gr.201574.115 · Cited by 81
Gene therapy of hemoglobinopathies: progress and future challenges
Ikawa, Y., Miccio, A., Magrin, E., Kwiatkowski, J. L., Rivella, S., & Cavazzana, M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz172 · Cited by 86
Cell and Gene Therapy for the Beta-Thalassemias: Advances and Prospects
Mansilla-Soto, J., Riviere, I., Boulad, F., & Sadelain, M. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.037 · Cited by 83
Determinants of transcription factor regulatory range
Chen, C.-H., Zheng, R., Tokheim, C., Dong, X., Fan, J., Wan, C., Tang, Q., Brown, M., Liu, J. S., Meyer, C. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16106-x · Cited by 85
Fetal haemoglobin induction in sickle cell disease
Paikari, A., & Sheehan, V. (2017) · British Journal of Haematology · doi:10.1111/bjh.15021 · Cited by 90
Mason, D. M., Weber, C. R., Parola, C., Meng, S. M., Greiff, V., Kelton, W., & Reddy, S. T. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky550 · Cited by 87
Integrated design, execution, and analysis of arrayed and pooled CRISPR genome-editing experiments
Canver, M. C., Haeussler, M., Bauer, D. E., Orkin, S. H., Sanjana, N. E., Shalem, O., Yuan, G., Zhang, F., Concordet, J., & Pinello, L. (2018) · Nature Protocols · doi:10.1038/nprot.2018.005 · Cited by 91
Self-citationCromer, M. K., Camarena, J., Martin, R. M., Lesch, B. J., Vakulskas, C. A., Bode, N. M., Kurgan, G., Collingwood, M. A., Rettig, G. R., Behlke, M. A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01284-y · Cited by 82
Potent and uniform fetal hemoglobin induction via base editing
Mayuranathan, T., Newby, G. A., Feng, R., Yao, Y., Mayberry, K. D., Lazzarotto, C. R., Li, Y., Levine, R. M., Nimmagadda, N., Dempsey, E., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01434-7 · Cited by 86
Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia
Xu, S., Luk, K., Yao, Q., Shen, A. H., Zeng, J., Wu, Y., Luo, H., Brendel, C., Pinello, L., Chui, D. H. K., et al. (2019) · Blood · doi:10.1182/blood-2019-01-895094 · Cited by 81
Self-citationZNF410 represses fetal globin by singular control of CHD4
Vinjamur, D. S., Yao, Q., Cole, M. A., McGuckin, C., Ren, C., Zeng, J., Hossain, M. A., Luk, K., Wolfe, S. A., Pinello, L., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00843-w · Cited by 83
Self-citationScalable Functional Assays for the Interpretation of Human Genetic Variation
Tabet, D. R., Parikh, V. N., Mali, P., Roth, F. P., & Claussnitzer, M. (2022) · Annual Review of Genetics · doi:10.1146/annurev-genet-072920-032107 · Cited by 84
β-Thalassemia intermedia: a comprehensive overview and novel approaches
Asadov, C. D., Alimirzoyeva, Z., Mammadova, T., Aliyeva, G., Gafarova, S., & Mammadov, J. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2411-9 · Cited by 81
Ultraconserved enhancer function does not require perfect sequence conservation
Snetkova, V., Ypsilanti, A. R., Akiyama, J. A., Mannion, B. J., Plajzer-Frick, I., Novak, C. S., Harrington, A. N., Pham, Q. T., Kato, M., Zhu, Y., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00812-3 · Cited by 79
Mapping genetic effects on cellular phenotypes with “cell villages”
Mitchell, J. M., Nemesh, J., Ghosh, S., Handsaker, R. E., Mello, C. J., Meyer, D., Raghunathan, K., de Rivera, H., Tegtmeyer, M., Hawes, D., et al. (2020) · doi:10.1101/2020.06.29.174383 · Cited by 63
Widespread Enhancer Activity from Core Promoters
Medina-Rivera, A., Santiago-Algarra, D., Puthier, D., & Spicuglia, S. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.03.004 · Cited by 78
Molecular Basis and Genetic Modifiers of Thalassemia
Tesio, N., & Bauer, D. E. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.12.001 · Cited by 91
Self-citationSungalee, S., Liu, Y., Lambuta, R. A., Katanayeva, N., Donaldson Collier, M., Tavernari, D., Roulland, S., Ciriello, G., & Oricchio, E. (2021) · Nature Genetics · doi:10.1038/s41588-021-00842-x · Cited by 70
Genome-scale CRISPR pooled screens
Sanjana, N. E. (2016) · Analytical Biochemistry · doi:10.1016/j.ab.2016.05.014 · Cited by 81
Self-citationHuang, P., Peslak, S. A., Lan, X., Khandros, E., Yano, J. A., Sharma, M., Keller, C. A., Giardine, B. M., Qin, K., Abdulmalik, O. Y., et al. (2020) · Blood · doi:10.1182/blood.2020005301 · Cited by 77
Woodworth, M. B., Greig, L. C., Liu, K. X., Ippolito, G. C., Tucker, H. O., & Macklis, J. D. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.064 · Cited by 75
Mammalian Transcription Factor Networks: Recent Advances in Interrogating Biological Complexity
Wilkinson, A. C., Nakauchi, H., & Göttgens, B. (2017) · Cell Systems · doi:10.1016/j.cels.2017.07.004 · Cited by 76
Dürr, J., Papareddy, R. K., Nakajima, K., & Gutierrez‐Marcos, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-22667-1 · Cited by 79
Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine
Azeez, S. S., Hamad, R. S., Hamad, B., Shekha, M. S., & Bergsten, P. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1509924 · Cited by 88
Versatile and robust genome editing with Streptococcus thermophilus CRISPR1-Cas9Preprint
Agudelo, D., Carter, S., Velimirovic, M., Duringer, A., Rivest, J.-F., Levesque, S., Loehr, J., Mouchiroud, M., Cyr, D., Waters, P. J., et al. (2020) · Genome Research · doi:10.1101/gr.255414.119 · Cited by 75
An erythroid-specific ATP2B4 enhancer mediates red blood cell hydration and malaria susceptibility
Lessard, S., Gatof, E. S., Beaudoin, M., Schupp, P. G., Sher, F., Ali, A., Prehar, S., Kurita, R., Nakamura, Y., Baena, E., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94378 · Cited by 76
Self-citationAutologous Stem-Cell-Based Gene Therapy for Inherited Disorders: State of the Art and Perspectives
Staal, F. J. T., Aiuti, A., & Cavazzana, M. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00443 · Cited by 77
Li, Q., Sapkota, M., & van der Knaap, E. (2020) · Horticulture Research · doi:10.1038/s41438-020-0258-8 · Cited by 73
Martyn, G. E., Wienert, B., Kurita, R., Nakamura, Y., Quinlan, K. G. R., & Crossley, M. (2019) · Blood · doi:10.1182/blood-2018-07-863951 · Cited by 75
Self-citationHou, G., Harley, I. T. W., Lu, X., Zhou, T., Xu, N., Yao, C., Qin, Y., Ouyang, Y., Ma, J., Zhu, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20460-1 · Cited by 75
Sellar, R. S., Sperling, A. S., Slabicki, M. M., Gasser, J. A., McConkey, M. E., Donovan, K. A., Mageed, N., Adams, D. N., Zou, C., Miller, P. G., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153514 · Cited by 76
Perenthaler, E., Yousefi, S., Niggl, E., & Barakat, T. S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00352 · Cited by 75
Reactivation of γ-globin expression through Cas9 or base editor to treat β-hemoglobinopathies
Wang, L., Li, L., Ma, Y., Hu, H., Li, Q., Yang, Y., Liu, W., Yin, S., Li, W., Fu, B., et al. (2020) · Cell Research · doi:10.1038/s41422-019-0267-z · Cited by 76
Self-citationApplications of CRISPR-Cas9 as an Advanced Genome Editing System in Life Sciences
Tavakoli, K., Pour‐Aboughadareh, A., Kianersi, F., Poczai, P., Etminan, A., & Shooshtari, L. (2021) · BioTech · doi:10.3390/biotech10030014 · Cited by 84
BCL11A: a potential diagnostic biomarker and therapeutic target in human diseases
Yin, J., Xie, X., Ye, Y., Wang, L., & Che, F. (2019) · Bioscience Reports · doi:10.1042/bsr20190604 · Cited by 73
Li, C., Wang, H., Georgakopoulou, A., Gil, S., Yannaki, E., & Lieber, A. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.001 · Cited by 73
Ravi, N. S., Wienert, B., Wyman, S. K., Bell, H. W., George, A., Mahalingam, G., Vu, J. T., Prasad, K. M., Bandlamudi, B. P., Devaraju, N., et al. (2022) · eLife · doi:10.7554/elife.65421 · Cited by 70
Self-citationDifferent Methods of Delivering CRISPR/Cas9 Into Cells
Chandrasekaran, A. P., Song, M., Kim, K.-S., & Ramakrishna, S. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2018.05.001 · Cited by 73
High-throughput PRIME-editing screens identify functional DNA variants in the human genome
Ren, X., Yang, H., Nierenberg, J. L., Sun, Y., Chen, J., Beaman, C., Pham, T., Nobuhara, M., Takagi, M. A., Narayan, V., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.11.021 · Cited by 70
Towards a new era in medicine: therapeutic genome editing
Porteus, M. H. (2015) · Genome Biology · doi:10.1186/s13059-015-0859-y · Cited by 69
Khosravi, M. A., Abbasalipour, M., Concordet, J., Berg, J. V., Zeinali, S., Arashkia, A., Azadmanesh, K., Buch, T., & Karimipoor, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.04.042 · Cited by 71
Metadata
- Authors
- Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., Luc, S., Kurita, R., Nakamura, Y., Fujiwara, Y., Maeda, T., Yuan, G.-C., Zhang, F., Orkin, S. H., & Bauer, D. E.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Broad Institute (US)
- RIKEN BioResource Research Center (JP)
- University of Tsukuba (JP)
- Brigham and Women's Hospital (US)
- Corresponding author
- Zhang, Feng
- Orkin, Stuart H.
- Bauer, Daniel E.
- ORCID
- Venue
- Nature
- Published
- 2015-09-16
- Volume
- 527
- Issue
- 7577
- Pages
- 192-197
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4644101
- OpenAlex
- W1855348513
- Cited by
- 886
- References
- 65
- Citations by year
- 2026: 43 · 2025: 72 · 2024: 76 · 2023: 79 · 2022: 68 · 2021: 91 · 2020: 85 · 2019: 92 · 2018: 87 · 2017: 94 · 2016: 89 · 2015: 8
- FWCI
- 51.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion)
- PMC
- Funders
- Howard Hughes Medical Institute
- U.S. Public Health Service (R01 A1084905)
- National Heart, Lung, and Blood Institute (P01HL032262, R01HL032259, R01HL119099)
- National Institute of Mental Health (DP1MH100706, R01MH110049)
- National Human Genome Research Institute (K99HG008171, R01HG005085, K99HG008399)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK049216, 5R01-DK097768, R01DK097768, F30DK103359, K08DK093705)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- BCL11A, enhancers, CRISPR/Cas9, fetal hemoglobin, sickle cell disease, beta-thalassemia, enhancer architecture, erythroblasts
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Animals, Base Sequence, Carrier Proteins, Cells, Cultured, DNA-Binding Proteins, Enhancer Elements, Genetic, Erythroblasts, Fetal Hemoglobin, Genetic Engineering, Humans, Molecular Sequence Data, Nuclear Proteins, Organ Specificity, Repressor Proteins, Species Specificity, Reproducibility of Results, Mutagenesis, Genome, Mice, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
